Biogen shares are down 36% from March, a decline that was primarily driven by weaker than expected (5% off forecasts) second quarter sales in addition to lowered sales guidance. We feel this stock could be oversold and could well post gains over the next year.
from Peter Garnry - Authored content http://ift.tt/1JP2CIW
via IFTTT
#SaxoStrats: Biogen hitting bottom?
ad
Enregistrer un commentaire